RecruitingNot ApplicableNCT07579845

Clinical Trial Evaluating the Impact of a Dietary Supplement Containing Humic and Fulvic Acid on Epigenetic Markers of Biological Age, Detoxification, Inflammation, and Oxidative Stress

Sponsor

OvationLab

Enrollment

60 participants

Start Date

May 5, 2026

Study Type

INTERVENTIONAL

Conditions

Inflammation Biological Aging Detoxification

Summary

The primary purpose of this study is to evaluate the impact of BioToxin Binder, a commercially available dietary supplement containing humic and fulvic acid, on markers of biologic age, detoxification, inflammation, oxidative stress, and related markers among generally healthy adults.

Eligibility

Min Age: 40 Years

Inclusion Criteria2

Adult females or males age ≥ 40 years
Ability to read and speak English

Exclusion Criteria6

Current use of a dietary supplement containing fulvic or humic acid
Current use of other binder dietary supplements, including activated charcoal, modified citrus pectin, bentonite clay, or chlorella
Known allergies to any ingredients in the product
Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks
Current diagnosis of a chronic health condition (e.g., cancer, heart failure, history of pancreatitis, type I or II diabetics on insulin) deemed clinically contraindicated for the study protocol
Participants unable to provide consent

Interested in this trial?

Get notified about updates and connect with the research team.